Gene Therapy Firm Freeline Successfully Tops Up Series C

CEO Says $120m Financing Will Advance Key Clinical Programs

An expanded $120m series C financing will help Freeline advance its lead program in hemophilia B into a pivotal trial next year, CEO Theresa Heggie tells Scrip.

DNA
Freeline is developing curative gene therapies for chronic systemic disease. • Source: Shutterstock

Freeline Therapeutics Ltd. has topped up an original series C financing with a further $80m from specialist global institutional investors for a total of $120m. This will give the gene therapy specialist an extended financial runway for advancing its lead program in hemophilia B into a pivotal trial next year and its Phase I/II clinical program for Fabry disease as well as progressing its pipeline for Gaucher disease and hemophilia A, the UK-based group’s CEO told Scrip.

The augmented series C round was led by Novo Holdings A/S, Eventide Asset Management and Wellington Management Company, with additional...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip